CD19-specific CAR-T Cell Treatment of 115 Children and Young Adults with Acute B Lymphoblastic Leukemia: Long-Term Follow-up
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Chemotherapy has been the primary treatment for patients with B-cell acute lymphoblastic leukemia (B-ALL). However, there are still patients who are not sensitive to chemotherapy, including those with refractory/relapse (R/R) disease and those experiencing minimal residual disease (MRD) re-emergence. Chimeric antigen receptor-T lymphocytes (CAR-T) therapy may provide a new treatment option for these patients. Materials and Methods Our institution conducted a single-arm prospective clinical trial (ChiCTR-OPN-17013507) using CAR-T-19 to treat R/R B-ALL and MRD re-emergent patients. One hundred and fifteen patients, aged 1-25 years (median age, 8 years), were enrolled, including 67 R/R and 48 MRD re-emergent CD19-positive B-ALL patients. Results All patients achieved morphologic complete remission (CR), and within 1 month after infusion, 111 out of 115 (96.5%) patients achieved MRD-negative CR. With a median follow-up time of 48.4 months, the estimated 4-year leukemia-free survival (LFS) rate and overall survival (OS) rate were 68.7%±4.5% and 70.7%±4.3%, respectively. There were no significant differences in long-term efficacy observed among patients with different disease statuses before infusion (4-year OS: MRD re-emergence vs. R/R B-ALL, 70.6%±6.6% vs. 66.5%±6.1%, p=0.755; 4-year LFS: MRD re-emergence vs. R/R B-ALL, 67.3%±7.0% vs. 63.8%±6.2%, p=0.704). R/R B-ALL patients bridging to transplantation after CAR-T treatment had a superior OS and LFS compared to those who did not. However, for MRD re-emergent patients, there was no significant difference in OS and LFS, regardless of whether they underwent hematopoietic stem cell transplantation or not. Conclusion CD19 CAR-T therapy effectively and safely cures both R/R B-ALL and MRD re-emergent patients.
Abstract
Purpose Chemotherapy has been the primary treatment for patients with B-cell acute lymphoblastic leukemia (B-ALL). However, there are still patients who are not sensitive to chemotherapy, including those with refractory/relapse (R/R) disease and those experiencing minimal residual disease (MRD) re-emergence. Chimeric antigen receptor-T lymphocytes (CAR-T) therapy may provide a new treatment option for these patients. Materials and Methods Our institution conducted a single-arm prospective clinical trial (ChiCTR-OPN-17013507) using CAR-T-19 to treat R/R B-ALL and MRD re-emergent patients. One hundred and fifteen patients, aged 1-25 years (median age, 8 years), were enrolled, including 67 R/R and 48 MRD re-emergent CD19-positive B-ALL patients. Results All patients achieved morphologic complete remission (CR), and within 1 month after infusion, 111 out of 115 (96.5%) patients achieved MRD-negative CR. With a median follow-up time of 48.4 months, the estimated 4-year leukemia-free survival (LFS) rate and overall survival (OS) rate were 68.7%±4.5% and 70.7%±4.3%, respectively. There were no significant differences in long-term efficacy observed among patients with different disease statuses before infusion (4-year OS: MRD re-emergence vs. R/R B-ALL, 70.6%±6.6% vs. 66.5%±6.1%, p=0.755; 4-year LFS: MRD re-emergence vs. R/R B-ALL, 67.3%±7.0% vs. 63.8%±6.2%, p=0.704). R/R B-ALL patients bridging to transplantation after CAR-T treatment had a superior OS and LFS compared to those who did not. However, for MRD re-emergent patients, there was no significant difference in OS and LFS, regardless of whether they underwent hematopoietic stem cell transplantation or not. Conclusion CD19 CAR-T therapy effectively and safely cures both R/R B-ALL and MRD re-emergent patients.
참고문헌 (21)
- Yu CH, "Clinical impact of minimal residual disease and genetic subtypes on the prognosis of childhood acute lymphoblastic leukemia", Cancer, 129, pp.790~802 (2023)
- Cui L, "Outcome of children with newly diagnosed acute lymphoblastic leukemia treated with CCLG-ALL 2008 : The first nation-wide prospective multicenter study in China", Am J Hematol, 93, pp.913~920 (2018)
- Koh KN, "Outcome of reinduction chemotherapy with a modified dose of idarubicin for children with marrow-relapsed acute lymphoblastic leukemia : results of the Childhood Acute Lym-phoblastic Leukemia(CALL)-0603 Study", J Korean Med Sci, 32, pp.642~649 (2017)
- Wang Y, "Re-emergence of minimal residual disease detected by flow cytometry predicts an adverse outcome in pediatric acute lymphoblastic leukemia", Front Oncol, 10, pp.596677~ (2020)
- Li Z, "CAR-T therapy followed by allogeneic hematopoietic stem cell transplantation for refractory", relapsed acute B lymphocytic leukemia : Long-term follow-up results, 2022, pp.12, 1048296~
- Park JH, "Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia", N Engl J Med, 378, pp.449~459 (2018)
- Zhang X, "Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia", Cancer Immunol Immunother, 71, pp.689~703 (2022)
- An F, "Influence of patient characteristics on chimeric antigen receptor T cell therapy in B-cell acute lymphoblastic leukemia", Nat Commun, 11, pp.5928~ (2020)
- Hay KA, "Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy", Blood, 133, pp.1652~1663 (2019)
- Hu GH, "Unmanipulated haploidentical hematopoietic stem cell transplantation is an excellent option for children and young adult relapsed", refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after CAR-T-cell therapy, 2021, pp.35, 3092~3100
- Hu GH, "Chimeric antigens receptor T cell therapy improve the prognosis of pediatric acute lymphoblastic leukemia with persistent", recurrent minimal residual disease in first complete remission, 2021, pp.12, 731435~
- Lee DW, "ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells", Biol Blood Marrow Transplant, 25, pp.625~638 (2019)
- Zhang X, "Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features", Blood Adv, 4, pp.2325~2338 (2020)
- Shah NN, "Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL", J Clin Oncol, 39, pp.1650~1659 (2021)
- Eldfors S, "Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia", Leukemia, 31, pp.51~57 (2017)
- Lenk L, "Involvement of the central nervous system in acute lymphoblastic leukemia : opinions on molecular mechanisms and clinical implications based on recent data", Cancer Metastasis Rev, 39, pp.173~187 (2020)
- Xu X, "Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies", Front Immunol, 10, pp.2664~ (2019)
- Zhang X, "Advances in the development of chimeric antigen receptor-T-cell therapy in B-cell acute lymphoblastic leukemia", Chin Med J(Engl), 133, pp.474~482 (2020)
- Pui CH, "Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia : a prospective study", Lancet Oncol, 16, pp.465~474 (2015)
- Pemmaraju N, "Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission", Am J Hematol, 92, pp.279~285 (2017)
- Winters A, "Moving immunotherapy into the front line in ALL", Hematology Am Soc Hematol Educ Program, 2019, pp.209~217 (2019)